HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR - Free Report) in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock.
VYGR has been the subject of several other reports. StockNews.com cut Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the company an "overweight" rating in a report on Wednesday, March 12th. Canaccord Genuity Group decreased their price target on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Thursday, March 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $13.97.
Check Out Our Latest Stock Report on VYGR
Voyager Therapeutics Price Performance
Shares of Voyager Therapeutics stock traded up $0.18 on Tuesday, reaching $3.17. 313,556 shares of the company traded hands, compared to its average volume of 461,459. The firm has a market capitalization of $175.01 million, a PE ratio of 4.46 and a beta of 1.02. The company has a 50 day moving average of $3.95 and a 200 day moving average of $5.39. Voyager Therapeutics has a 52 week low of $2.75 and a 52 week high of $9.55.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The business had revenue of $4.39 million for the quarter, compared to analysts' expectations of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period last year, the company earned $1.25 earnings per share. As a group, analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.
Insider Activity
In related news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the transaction, the chief executive officer now owns 430,931 shares of the company's stock, valued at $1,478,093.33. This represents a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 15,163 shares of company stock worth $59,158. 4.53% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Voyager Therapeutics
Several hedge funds have recently added to or reduced their stakes in VYGR. Wellington Management Group LLP raised its holdings in shares of Voyager Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 261,251 shares of the company's stock valued at $1,481,000 after buying an additional 31,882 shares in the last quarter. Vestal Point Capital LP raised its stake in shares of Voyager Therapeutics by 151.0% during the fourth quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company's stock worth $6,974,000 after acquiring an additional 740,000 shares in the last quarter. Virtus Investment Advisers Inc. lifted its holdings in shares of Voyager Therapeutics by 59.0% in the 4th quarter. Virtus Investment Advisers Inc. now owns 20,105 shares of the company's stock worth $114,000 after acquiring an additional 7,457 shares during the last quarter. Tema Etfs LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth approximately $85,000. Finally, Man Group plc purchased a new stake in shares of Voyager Therapeutics in the 4th quarter valued at $234,000. Institutional investors own 48.03% of the company's stock.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Further Reading
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
